Evidence map›Paper›PMID 29162143›Full record

ArticleVirology journal2017

Prevalence and risk of hepatitis E virus infection in the HIV population of Nepal.

Ananta Shrestha, Anurag Adhikari, Manjula Bhattarai, Ramanuj Rauniyar, Jose D Debes, André Boonstra, Thupten K Lama, Mamun Al Mahtab, Amna Subhan Butt, Sheikh Mohammad Fazle Akbar and 4 more

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. [Strengthening the study of chronic hepatitis E].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Hepatitis E Infection in HIV-Infected Patients.Frontiers in microbiology · 2019
    Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 7 countries.

Ananta ShresthaLiver Foundation Nepal, Kathmandu, Nepal.
Anurag AdhikariKathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.
Manjula BhattaraiKathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.
Ramanuj RauniyarKathmandu Research Institute for Biological Sciences, Lalitpur, Nepal.
Jose D DebesDepartment of Medicine, University of Minnesota, Minneapolis, MN, USA.
André BoonstraDepartment of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
Thupten K LamaCivil Service Hospital of Nepal, Kathmandu, Nepal.
Mamun Al MahtabDepartment of Hepatology, BangabandhuShiekhMujib Medical University, Dhaka, Bangladesh.
Amna Subhan ButtDepartment of Medicine, The Aga Khan University, Karachi, Pakistan.
Sheikh Mohammad Fazle AkbarToshiba General Hospital, Tokyo, Japan.
Nirmal AryalVirology Unit, Central Department of Biotechnology, Tribhuvan University, Kathmandu, Nepal.
Sapana KarnSt. Xavier's College Maitighar, Kathmandu, Nepal.
Krishna Das ManandharVirology Unit, Central Department of Biotechnology, Tribhuvan University, Kathmandu, Nepal.
Birendra Prasad GuptaVirology Unit, Central Department of Biotechnology, Tribhuvan University, Kathmandu, Nepal. birendraphd@gmail.com.
Tribhuvan University · NPAga Khan University · PKBangabandhu Sheikh Mujib Medical University · BDCivil Service Hospital · NPErasmus University Rotterdam · NLSt Xavier’s College · INToshiba General Hospital · JPUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfection with the hepatitis E virus (HEV) can cause acute hepatitis in endemic areas in immune-competent hosts, as well as chronic infection in immune-compromised subjects in non-endemic areas. Most studies assessing HEV infection in HIV-infected populations have been performed in developed countries that are usually affected by HEV genotype 3. The objective of this study is to measure the prevalence and risk of acquiring HEV among HIV-infected individuals in Nepal.

methodsWe prospectively evaluated 459 Human Immunodeficiency Virus (HIV)-positive individuals from Nepal, an endemic country for HEV, for seroprevalence of HEV and assessed risk factors associated with HEV infection. All individuals were on antiretroviral therapy and healthy blood donors were used as controls.

resultsWe found a high prevalence of HEV IgG (39.4%) and HEV IgM (15.3%) in HIV-positive subjects when compared to healthy HIV-negative controls: 9.5% and 4.4%, respectively (OR: 6.17, 95% CI 4.42-8.61, p < 0.001 and OR: 3.7, 95% CI 2.35-5.92, p < 0.001, respectively). Individuals residing in the Kathmandu area showed a significantly higher HEV IgG seroprevalance compared to individuals residing outside of Kathmandu (76.8% vs 11.1%, OR: 30.33, 95% CI 18.02-51.04, p = 0.001). Mean CD4 counts, HIV viral load and presence of hepatitis B surface antigen correlated with higher HEV IgM rate, while presence of hepatitis C antibody correlated with higher rate of HEV IgG in serum. Overall, individuals with HEV IgM positivity had higher levels of alanine aminotransferase (ALT) than IgM negative subjects, suggesting active acute infection. However, no specific symptoms for hepatitis were identified.

conclusionsHIV-positive subjects living in Kathmandu are at higher risk of acquiring HEV infection as compared to the general population and to HIV-positive subjects living outside Kathmandu.

Indexed as

AdultAlanine TransaminaseAspartate AminotransferasesCD4 Lymphocyte CountCoinfectionFemaleHepatitis AntibodiesHepatitis EHepatitis E virusHIV InfectionsHumansImmunoglobulin GImmunoglobulin MMaleMiddle AgedNepalAlanine TransaminaseAspartate AminotransferasesHepatitis AntibodiesImmunoglobulin GImmunoglobulin MRNA, ViralBlood donorHEVHIVImmunocompromisedKathmandu

Identifiers

PMID29162143
PMCPMC5696774
OpenAlexW2769846765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.